{
    "nct_id": "NCT02807181",
    "official_title": "Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma",
    "inclusion_criteria": "* Willing, able and mentally competent to provide written informed consent.\n* Aged 18 years or older.\n* Histologically or cytologically confirmed unresectable and non-ablatable intrahepatic cholangiocarcinoma.\n* Liver-only or liver predominant intrahepatic cholangiocarcinoma. Patient are permitted to have loco-regional lymph node involvement defined as: portal LN </= to 2 cm and/or para aortic LN </= to 1.5 cm in longest diameter, and/or up to 2 indeterminate lung lesions < 1 cm if these lung lesions are positron emission tomography (PET) negative.\n* Chemotherapy naÃ¯ve. Adjuvant chemotherapy is not permitted.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Adequate hematological function defined as:\n\nHemoglobin >/= 10g/dL White Blood Cell count (WBC) >/= 3.0 x 10^9/L Absolute neutrophil count (ANC) >/= 1.5 x 10^9/L Platelet count >/= 100,000/mm^3 - Adequate liver function defined as: Total bilirubin </= 30 umol/L (1.75 mg/dL) Albumin >/= 30 g/L\n\n- Adequate renal function defined as: Serum urea and serum creatinine < 1.5 times upper limit of normal (ULN) Creatinine clearance >/= 45 ml/min (calculated with Cockcroft-Gault Equation)\n\n* Life expectancy of at least 3 months without any active treatment\n* Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active use an acceptable method of contraception during the study.\n* Male patients must be surgically sterile or if sexually active must use an acceptable method of contraception during the study.\n* Considered suitable to receive either regimen in the clinical judgement of the treating investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with only non-measurable lesions in the liver according to RECIST criteria\n* Incomplete recovery from previous liver surgery, e.g. unresolved biliary tree obstruction or biliary sepsis or inadequate liver function\n* Biliary stent in situ\n* Main trunk Portal Vein Thrombosis (PVT)\n* Ascites, even if controlled with diuretics. (A minor peri-hepatic rim of ascites detected at imaging is acceptable).\n* Mixed hepatocellular carcinoma - intrahepatic cholangiocarcinoma (HCC-ICC) disease\n* History of prior malignancy. Exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, non-metastatic basal and/or squamous cell carcinomas of the skin, recurrent intra-hepatic cholangiocarcinoma post local treatment or any early stage (stage 1) malignancy adequately resected with curative intent at least 5 years prior to study entry\n* Suspicion of any bone metastasis/metastases or central nervous system metastasis/metastases on clinical or imaging examination.\n* Prior internal or external radiation delivered to the liver.\n* Pregnancy; breast feeding.\n* Participation within 28 days prior to randomization, in an active part of another clinical study that would compromise any of the endpoints of the study.\n* Evidence of ongoing active infection that may affect treatment feasibility or outcome.\n* Prior Whipple's procedure.",
    "miscellaneous_criteria": ""
}